earticle

영어

Hyaluronic acid-D-α-tocopherol succinate-(4-carboxybutyl)triphenyl phosphonium bromide (HA-TS-TPP)-based nanoparticles (NPs) aiming at CD44 receptor and sequential mitochondria targeting were designed for the delivery of lapatinib (LPT) to triple-negative breast cancer (TNBC). Although LPT is known as one of the dual tyrosine kinase inhibitors targeting for epidermal growth factor receptor (EGFR) and human EGFR2 (HER2), TNBC cells frequently have EGFR (+) and HER2 (-) profiles. Not only the HER2-independent anticancer potentials of LPT against TNBC, but also apoptosis-induction capabilities of TPP and TS were introduced to enhance the anticancer potencies of HA-TS-TPP/LPT NPs for TNBC. HA-TS-TPP/LPT NPs (mean diameter: 207 nm; polydispersity index: 0.19; zeta potential: -24 mV) were fabricated by self-assembly property. Compared to HA-TS/LPT NPs, the increased antiproliferation, enhanced apoptotic effects, and improved mitochondrial disruption capability were confirmed in MDA-MB-231 cells (as one of TNBC cells). The in vivo tumor targetability of HA-TS-TPP/LPT NPs was demonstrated in MDA-MB-231 tumor-implanted mouse models with real-time optical imaging studies. After intravenous injection, HA-TS-TPP/LPT NPs achieved better antitumor profiles rather than the other tested groups. All these results indicate that HA-TS-TPP/LPT NPs may be one of promising candidates for efficient TNBC therapy.